NO752568L - - Google Patents
Info
- Publication number
- NO752568L NO752568L NO752568A NO752568A NO752568L NO 752568 L NO752568 L NO 752568L NO 752568 A NO752568 A NO 752568A NO 752568 A NO752568 A NO 752568A NO 752568 L NO752568 L NO 752568L
- Authority
- NO
- Norway
- Prior art keywords
- gel
- diagnostic reagent
- erythrocytes
- virus
- reagent according
- Prior art date
Links
- 210000003743 erythrocyte Anatomy 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 52
- 239000003153 chemical reaction reagent Substances 0.000 claims description 46
- 241000700605 Viruses Species 0.000 claims description 40
- 230000000813 microbial effect Effects 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 30
- 230000000295 complement effect Effects 0.000 claims description 28
- 210000001124 body fluid Anatomy 0.000 claims description 19
- 239000010839 body fluid Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 14
- 241000712461 unidentified influenza virus Species 0.000 claims description 14
- 230000015556 catabolic process Effects 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 241001494479 Pecora Species 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 7
- 241000700199 Cavia porcellus Species 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 241000710799 Rubella virus Species 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 206010037151 Psittacosis Diseases 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000000417 fungicide Substances 0.000 claims description 5
- 201000000901 ornithosis Diseases 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 241000588832 Bordetella pertussis Species 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007923 nasal drop Substances 0.000 claims description 3
- 229940100662 nasal drops Drugs 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 229910021555 Chromium Chloride Inorganic materials 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000607626 Vibrio cholerae Species 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 2
- 229940118696 vibrio cholerae Drugs 0.000 claims description 2
- 241000282555 Erythrocebus patas Species 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- 239000007822 coupling agent Substances 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 241001430197 Mollicutes Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 239000000499 gel Substances 0.000 description 49
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 206010022000 influenza Diseases 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010024887 Louping ill Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/559—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB32050/74A GB1501395A (en) | 1974-07-19 | 1974-07-19 | Viral anti-body detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO752568L true NO752568L (fi) | 1976-01-20 |
Family
ID=10332393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO752568A NO752568L (fi) | 1974-07-19 | 1975-07-18 |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5135418A (fi) |
| AT (1) | AT352289B (fi) |
| AU (1) | AU500101B2 (fi) |
| BE (1) | BE831554A (fi) |
| BR (1) | BR7504584A (fi) |
| CA (1) | CA1054935A (fi) |
| CH (1) | CH621874A5 (fi) |
| DE (1) | DE2532283A1 (fi) |
| DK (1) | DK328075A (fi) |
| ES (1) | ES439520A1 (fi) |
| FI (1) | FI752081A (fi) |
| FR (1) | FR2278308A1 (fi) |
| GB (1) | GB1501395A (fi) |
| IE (1) | IE41633B1 (fi) |
| IL (1) | IL47736A (fi) |
| IT (1) | IT1048304B (fi) |
| NL (1) | NL7508624A (fi) |
| NO (1) | NO752568L (fi) |
| NZ (1) | NZ178160A (fi) |
| SE (1) | SE7508228L (fi) |
| ZA (1) | ZA754643B (fi) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146852A (en) * | 1979-01-31 | 1983-05-24 | Koichi Kondo | Reagent for latex agglutination |
-
1974
- 1974-07-19 GB GB32050/74A patent/GB1501395A/en not_active Expired
-
1975
- 1975-07-17 ES ES439520A patent/ES439520A1/es not_active Expired
- 1975-07-18 IL IL47736A patent/IL47736A/xx unknown
- 1975-07-18 AU AU83175/75A patent/AU500101B2/en not_active Expired
- 1975-07-18 IT IT50589/75A patent/IT1048304B/it active
- 1975-07-18 JP JP50088187A patent/JPS5135418A/ja active Pending
- 1975-07-18 FI FI752081A patent/FI752081A/fi not_active Application Discontinuation
- 1975-07-18 FR FR7522492A patent/FR2278308A1/fr active Granted
- 1975-07-18 CH CH944975A patent/CH621874A5/de not_active IP Right Cessation
- 1975-07-18 NL NL7508624A patent/NL7508624A/xx not_active Application Discontinuation
- 1975-07-18 BE BE158461A patent/BE831554A/xx unknown
- 1975-07-18 AT AT558875A patent/AT352289B/de not_active IP Right Cessation
- 1975-07-18 NZ NZ178160A patent/NZ178160A/xx unknown
- 1975-07-18 SE SE7508228A patent/SE7508228L/ not_active Application Discontinuation
- 1975-07-18 CA CA231,818A patent/CA1054935A/en not_active Expired
- 1975-07-18 DK DK328075A patent/DK328075A/da unknown
- 1975-07-18 DE DE19752532283 patent/DE2532283A1/de not_active Withdrawn
- 1975-07-18 ZA ZA754643A patent/ZA754643B/xx unknown
- 1975-07-18 IE IE1605/75A patent/IE41633B1/en unknown
- 1975-07-18 NO NO752568A patent/NO752568L/no unknown
- 1975-07-18 BR BR7504584*A patent/BR7504584A/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH621874A5 (en) | 1981-02-27 |
| AT352289B (de) | 1979-09-10 |
| ATA558875A (de) | 1979-02-15 |
| FR2278308B1 (fi) | 1979-03-09 |
| NL7508624A (nl) | 1976-01-21 |
| BR7504584A (pt) | 1976-07-06 |
| ES439520A1 (es) | 1977-04-01 |
| IL47736A (en) | 1978-07-31 |
| FR2278308A1 (fr) | 1976-02-13 |
| NZ178160A (en) | 1978-06-20 |
| FI752081A (fi) | 1976-01-20 |
| IL47736A0 (en) | 1975-10-15 |
| JPS5135418A (fi) | 1976-03-25 |
| DE2532283A1 (de) | 1976-01-29 |
| BE831554A (fr) | 1976-01-19 |
| CA1054935A (en) | 1979-05-22 |
| IT1048304B (it) | 1980-11-20 |
| ZA754643B (en) | 1977-02-23 |
| DK328075A (da) | 1976-01-20 |
| AU8317575A (en) | 1977-01-20 |
| SE7508228L (sv) | 1976-01-20 |
| GB1501395A (en) | 1978-02-15 |
| IE41633B1 (en) | 1980-02-13 |
| AU500101B2 (en) | 1979-05-10 |
| IE41633L (en) | 1976-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120107829A1 (en) | Stabilizing compositions for immobilized biomolecules | |
| Schaffer et al. | Purification and properties of poliovirus | |
| Swanson et al. | IgE and IgG antibodies to β-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine | |
| DK161219B (da) | Proeveudstyr og fremgangsmaade til bestemmelse af streptococcus a | |
| US4176174A (en) | Viral antibody diagnostic test system | |
| US4284725A (en) | Virus titration and identification system | |
| EA013228B1 (ru) | Способ получения обогащённого поликлонального антитела, высокоспецифичного к антигену поверхностного полисахарида липоарабиноманнана микобактерий, и способы его применения | |
| JPS60237365A (ja) | 免疫細胞化学用顕微鏡対照スライド | |
| NO752568L (fi) | ||
| EP3608672B1 (en) | Crude native hapten-based indirect elisa assay kit and lyophilised controls for the confirmatory diagnosis of bovine brucellosis in blood serum and milk by animal and tank | |
| Sosa-Martinez et al. | Studies on a complement fixation test for herpes simplex | |
| USRE28548E (en) | Method and reagents for the diagnosis of viral diseases | |
| Grayston et al. | Adenoviruses. I. The effect of total incubation time in HeLa cell cultures on the isolation rate | |
| Hanson et al. | Properties of duck hepatitis virus | |
| Bar-Joseph et al. | Booster immunization with a partially purified citrus tristeza virus (CTV) preparation after priming with recombinant CTV coat protein enhances the binding capacity of capture antibodies by ELISA | |
| RU2688334C1 (ru) | Способ определения специфической активности антирабического иммуноглобулина на клеточной культуре с применением атомно-силовой микроскопии | |
| RU2435589C2 (ru) | Состав консервирующей добавки к контрольным материалам, используемым при серодиагностике сифилиса | |
| Thraenhart et al. | Standardization of a rapid modified micro-neuraminidase-inhibition test (Essen-NIT) for influenza virus-neuraminidase antibody assay and comparison with the WHO method | |
| SU712441A1 (ru) | Способ индикации | |
| Corbel et al. | Soluble antigens obtained from influenza virus by treatment with non-ionic detergent | |
| EP0030016A2 (en) | Method of preserving monolayers of tissue culture cells, and tissue culture cells so preserved | |
| RU2064794C1 (ru) | Средство для определения степени аттенуации вируса полиомиелита | |
| Al-aesayi et al. | Epidemiological Study on Rift Valley Fever Virus among Domestic Animals in Taiz Governorate (Yemen) | |
| Paul et al. | Rubella precipitin response in natural infection and in vaccination | |
| SU1084295A1 (ru) | Способ определени адгезивных свойств микроорганизмов,вызывающих кишечные инфекции |